Literature DB >> 26797780

Multimodality treatment of intrahepatic cholangiocarcinoma: A review.

Kerri A Simo1,2,3, Laura E Halpin3, Nicole M McBrier1,2, Jacob A Hessey4, Erin Baker5, Samuel Ross5, Ryan Z Swan5, David A Iannitti5, John B Martinie5.   

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary hepatic cancer in the United States. Currently, curative treatment involves aggressive surgery. Chemotherapy and radiation treatments have been used for unresectable tumors with some success. Optimizing the use of current and developing novel multimodality treatment for iCCA is essential to improving outcomes.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  intrahepatic cholangiocarcinoma; multimodality

Mesh：

Substances：

Year:  2016        PMID： 26797780     DOI： 10.1002/jso.24093

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  20 in total

Review 1.  Ablative therapies for intrahepatic cholangiocarcinoma.

Authors:  Junichi Shindoh
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  [Overpression of miR-29b suppresses the proliferation and induces apoptosis of cholangiocarcinoma cells].

Authors:  Kun Cao; Liangquan Sun; Yewei Zhang; Tengfei Wang; Haiyang Li; Shi Zuo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-09-30

Review 3.  Therapeutic options for intrahepatic cholangiocarcinoma.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

4.  Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma.

Authors:  Sean P Martin; Samantha Ruff; Laurence P Diggs; Justin Drake; Reed I Ayabe; Zachary J Brown; Michael M Wach; Seth M Steinberg; Jeremy L Davis; Jonathan M Hernandez
Journal:  HPB (Oxford)       Date:  2018-08-20       Impact factor: 3.647

5.  Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.

Authors:  Suguru Yamashita; Eugene Jon Koay; Guillaume Passot; Rachna Shroff; Kanwal P Raghav; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Randa Tao; Ahmed Kaseb; Milind Javle; Christopher H Crane; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

Review 6.  Ablation of Intrahepatic Cholangiocarcinoma.

Authors:  Jennifer Sweeney; Nainesh Parikh; Ghassan El-Haddad; Bela Kis
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 7.  Surgical Therapy of Cholangiocarcinoma.

Authors:  Arnold Radtke; Alfred Königsrainer
Journal:  Visc Med       Date:  2016-11-30

8.  Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.

Authors:  Zhongzhi Jia; Ricardo Paz-Fumagalli; Gregory Frey; David M Sella; J Mark McKinney; Weiping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2016-11-08       Impact factor: 4.553

9.  Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.

Authors:  Alexandra Gangi; Jehan Shah; Nathan Hatfield; Johnna Smith; Jennifer Sweeney; Junsung Choi; Ghassan El-Haddad; Benjamin Biebel; Nainesh Parikh; Bulent Arslan; Sarah E Hoffe; Jessica M Frakes; Gregory M Springett; Daniel A Anaya; Mokenge Malafa; Dung-Tsa Chen; Yunyun Chen; Richard D Kim; Ravi Shridhar; Bela Kis
Journal:  J Vasc Interv Radiol       Date:  2018-07-02       Impact factor: 3.464

Review 10.  Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE.

Authors:  Brian M Currie; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.